Screener
10x Genomics, Inc. TXG Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $151.04M-12.6% | $150.84M-2.6% | $166.03M+0.6% | $149M-1.7% | $172.91M+12.9% | ||
| $38.54M-19.4% | $44.67M-9.7% | $52.99M-2.0% | $48.7M+7.6% | $47.82M-2.2% | ||
| $112.5M-10.1% | $106.18M+0.7% | $113.05M+1.9% | $100.31M-5.7% | $125.08M+20.0% | ||
| 74.5%+2.1pp | 70.4%+2.3pp | 68.1%+0.9pp | 67.3%-2.8pp | 72.3%+4.3pp | ||
| $56.79M-7.2% | $56.85M-11.5% | $55.97M-16.4% | $57.19M-13.6% | $61.22M-2.7% | ||
| $78.66M+5.7% | $66.38M-26.0% | $76.62M-18.3% | $75.36M-7.8% | $74.43M-10.4% | ||
| $132.05M+39.1% | $123.22M-14.9% | $132.59M-17.5% | $132.55M-10.4% | $94.96M-34.9% | ||
| -$19.56M-165% | -$17.05M+56.7% | -$19.54M+60.8% | -$32.24M+22.3% | $30.13M+172% | ||
| -12.9%-30.4pp | -11.3%+14.1pp | -11.8%+18.4pp | -21.6%+5.7pp | 17.4%+44.7pp | ||
| $0-100% | —— | $0— | -$3K-250% | $3K+200% | ||
| $910K-86.8% | $4.2M-27.9% | $4.35M+198% | $4.04M-42.7% | $6.87M+47.5% | ||
| -$18.65M-150% | -$12.85M+61.7% | -$15.19M+68.6% | -$28.21M+18.1% | $37M+200% | ||
| -$714K-129% | $623K-26.9% | $1.06M+63.4% | -$733K-156% | $2.46M+201% | ||
| -$17.93M-152% | -$13.47M+60.8% | -$16.25M+66.9% | -$27.47M+23.2% | $34.54M+191% | ||
| -11.9%-31.8pp | -8.9%+13.3pp | -9.8%+19.9pp | -18.4%+5.1pp | 20%+44.7pp | ||
| -$0.14-150% | -$0.10+64.3% | -$0.13+68.3% | -$0.22+26.7% | $0.28+188% | ||
| -$9.89M-126% | -$7.09M+77.4% | -$9.48M+76.9% | -$21.95M+32.5% | $37.94M+216% | ||
| -6.5%-28.5pp | -4.7%+15.5pp | -5.7%+19.2pp | -14.7%+6.7pp | 21.9%+43.3pp | ||
| -$19.56M-165% | -$17.05M+56.7% | -$19.54M+60.8% | -$32.24M+22.3% | $30.13M+172% |
FAQ
- What is 10x Genomics, Inc.'s revenue?
- 10x Genomics, Inc. (TXG) generated $616.9M in revenue over the trailing twelve months, down 4.3% year over year.
- Is 10x Genomics, Inc. profitable?
- 10x Genomics, Inc. is not currently profitable: it reported a net loss of $75.1M over the trailing twelve months, a -12.2% net margin.
- What are 10x Genomics, Inc.'s profit margins?
- Gross margin is 70.0% and operating margin is -14.3%, with a -12.2% net margin.
- What is 10x Genomics, Inc.'s earnings per share?
- 10x Genomics, Inc.'s diluted EPS over the trailing twelve months is $-0.59.
- Where does 10x Genomics, Inc.'s income statement data come from?
- Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
